When the Chances In­crease

Uzbekistan Today (English) - - SOCIAL ORBIT - Davlat Umarov

Cur­rently, the Min­istry of Health is con­sid­er­ing fur­ther im­prov­ing the de­vel­op­ment of the hema­tol­ogy ser­vice. In par­tic­u­lar, we are talk­ing about the trans­for­ma­tion of the Re­search In­sti­tute of Hema­tol­ogy and Blood Trans­fu­sion into a spe­cial­ized Repub­li­can Spe­cial­ized Sci­en­tific and Prac­ti­cal Med­i­cal Cen­ter.

“The re­or­ga­ni­za­tion of our med­i­cal in­sti­tu­tion should be a log­i­cal con­tin­u­a­tion of the work car­ried out here on the in­tro­duc­tion of mod­ern high-tech meth­ods of di­ag­no­sis and treat­ment,” said Pro­fes­sor Hamid Ka­ri­mov, head of the Cen­ter for Bone Mar­row Trans­plan­ta­tion. «This will al­low us to in­tro­duce a mixed type of fi­nanc­ing for these meth­ods of treat­ment, sim­i­lar to what is be­ing used to­day at the Vahi­dov Cen­ter for Surgery, Car­di­ol­ogy and other med­i­cal in­sti­tu­tions that have the same sta­tus. That is to say, that part of the cost of such treat­ment will be cov­ered by bud­getary funds, and the other - at the ex­pense of per­sonal funds of pa­tients. As a re­sult, all ex­ist­ing bar­ri­ers will be elim­i­nated for the timely re­ceipt of treat­ment by pa­tients, with­out leav­ing the repub­lic.”

Our reg­u­lar meet­ing with Pro­fes­sor Hamid Ka­ri­mov be­gan with these words. In ac­cor­dance with the edi­to­rial as­sign­ment within the frame­work of this meet­ing, the cor­re­spon­dents were to talk about the in­tro­duc­tion and ap­pli­ca­tion by spe­cial­ists of the Re­search In­sti­tute of Hema­tol­ogy and Blood Trans­fu­sion of all in­no­va­tions in the di­ag­no­sis and treat­ment of ma­lig­nant neo­plasms of lym­phatic and haematopoi­etic tis­sue (hemoblas­toses). These are the most com­mon tu­mor dis­eases, in other words all of what we have been talk­ing about over the past few years in our materials on the ac­tiv­i­ties of the In­sti­tute.

Ex­perts note that over the past 20 years, thanks to the de­vel­op­ment and im­ple­men­ta­tion of high-tech molec­u­lar bi­o­log­i­cal tech­nolo­gies, a real rev­o­lu­tion has taken place in the world med­i­cal prac­tice, which made it pos­si­ble to de­duce a sig­nif­i­cant part of hemoblas­toses from the cat­e­gory of “fa­tal” dis­eases. That is why the de­vel­op­ment of molec­u­lar medicine largely de­ter­mines the level of the en­tire medicine of the coun­try. In re­cent years, the Cen­ter for Trans­plan­ta­tion of Stem Cells from the Bone Mar­row has been es­tab­lished at the Re­search In­sti­tute of Hema­tol­ogy and Blood Trans­fu­sion, equipped with mod­ern high-tech lab­o­ra­tory and med­i­cal equipment, which makes it pos­si­ble to carry out the nec­es­sary di­ag­nos­tics and treat­ment at the high­est tech­no­log­i­cal level us­ing all ad­vanced tech­nolo­gies.

- About ten years ago, our in­sti­tute for the first time in the repub­lic, with the help of the char­i­ta­ble pro­gram of the com­pany No­var­tis Pharma (Switzer­land), be­gan to ap­ply meth­ods of treat­ment with drugs that se­lec­tively af­fect spe­cific gene mu­ta­tions (molec­u­lar-tar­geted ther­apy). This was a rev­o­lu­tion­ary break­through in the field of tar­geted an­ti­tu­mor ther­apy of cer­tain types of leukemia. Thanks to the char­ity pro­gram of this com­pany, our pa­tients have the op­por­tu­nity to re­ceive these ex­pen­sive medicines for free. At the same time, the com­pany puts only one con­di­tion for start­ing such a treat­ment - it is nec­es­sary to pro­vide the re­sults of lab­o­ra­tory stud­ies, ac­cord­ing to which it be­comes clear that the pro­vided drugs “Glivec” and “Tasigna» can re­ally help the pa­tient. The fact is that they are ef­fec­tive only for spe­cific forms of the dis­ease, - says Khamid Yakubovich. “How­ever, in the early years be­fore the com­ple­tion of equip­ping our lab­o­ra­tory with mod­ern, ex­pen­sive equipment in 2014, the num­ber of pa­tients who took ad­van­tage of this op­por­tu­nity was small. The rea­son is that for the nec­es­sary di­ag­nos­tics they were forced to travel to Rus­sia and other coun­tries, which re­quired fi­nan­cial costs. To­day, all the nec­es­sary tests are per­formed in our in­sti­tute, and the num­ber of those who re­ceive these medicines has al­ready reached al­most a thou­sand. The to­tal amount of do­nated aid to No­var­tis Pharma amounted to more than $ 115 mil­lion and over 8 mil­lion Swiss francs. At the same time, I par­tic­u­larly want to em­pha­size that we work on cer­ti­fied de­vices man­u­fac­tured by lead­ing com­pa­nies in Europe and the US, and sur­veys are con­ducted by spe­cial­ists who have com­pleted long in­tern­ship and re­train­ing cour­ses at lead­ing for­eign cen­ters in Ger­many, the Czech Repub­lic, Turkey, Rus­sia, Ja­pan and other coun­tries.

To date, the In­sti­tute has suc­cess­fully in­tro­duced a new molec­u­lar-bi­o­log­i­cal tech­nol­ogy for the ex­am­i­na­tion of pa­tients and a com­pre­hen­sive 4-level di­ag­no­sis and mon­i­tor­ing of leukemia ther­apy ac­cord­ing to the in­ter­na­tional IS scale (i.e. at the ge­nomic, ge­nomic, chro­mo­so­mal lev­els and at the level of the CD-cell re­cep­tors) . To date, more than 7,500 stud­ies have been per­formed us­ing this tech­nol­ogy. The di­ag­nos­tic and pre­dic­tive ef­fec­tive­ness of this tech­nol­ogy in the for­mat of the in­ter­na­tional IS scale reaches up to 99.9%. Most im­por­tantly, thanks to these new devel­op­ments, it be­came pos­si­ble to in­tro­duce into the clin­i­cal prac­tice two high-tech meth­ods for treat­ing hemoblas­toses, which al­low achiev­ing re­mis­sion and com­plete re­cov­ery in 7095% of pa­tients.

An­other in­no­va­tion, ap­plied at the In­sti­tute, is the treat­ment of pa­tients with their own hematopoi­etic stem cells. To date, more than 200 pa­tients with myeloma have un­der­gone stan­dard chemo­ther­apy, and 23 pa­tients with myeloma and 2 with lym­phoma have suc­cess­fully made high-tech ther­apy with their own stem cells for the first time in Cen­tral Asia. To date, there is the is­sue of ex­pand­ing the prac­tice of us­ing stem cell ther­apy. Hamid Ka­ri­mov em­pha­sized, that the re­or­ga­ni­za­tion of the in­sti­tute and in­tro­duc­tion of mixed forms of fi­nanc­ing of high-tech meth­ods of treat­ment can con­trib­ute to solve this task.

The to­tal fi­nan­cial sav­ings from all im­ple­men­ta­tions in the In­sti­tute amounted to more than $117 mil­lion, 3 mil­lion eu­ros and 8 mil­lion Swiss francs. But most im­por­tantly, the chances for re­cov­ery of the pa­tients in­creased, many cured pa­tients gained the op­por­tu­nity for a full life, started a fam­ily and con­tin­ued their work ac­tiv­i­ties.

- All these im­ple­men­ta­tions were due to fi­nan­cial sup­port of the In­sti­tute's projects, the sources of which in­cluded the State In­vest­ment Pro­gram, grant and ex­tra­bud­getary funds of the In­sti­tute, hu­man­i­tar­ian as­sis­tance from the Turk­ish Co­op­er­a­tion and Co­or­di­na­tion Agency (TICA) un­der the Prime Min­is­ter's Of­fice of Turkey and the in­ter­na­tional JIPAP pro­gram- noted Pro­fes­sor Hamid Ka­ri­mov.

The In­sti­tute has trained per­son­nel and cre­ated a ma­te­rial and tech­ni­cal base for car­ry­ing out not only trans­plan­ta­tion of stem cells, but also other or­gans and tis­sues. In ad­di­tion to the ex­pected re­or­ga­ni­za­tion of the in­sti­tute, other mea­sures are planned to strengthen the ma­te­rial and tech­ni­cal base of the in­sti­tute and en­sure un­in­ter­rupted pro­vi­sion of nec­es­sary con­sum­ables. This al­lows for more full-scale in­tro­duc­tion of stem cell al­lo­trans­plan­ta­tion and other high-tech meth­ods of di­ag­nos­tics and treat­ment into clin­i­cal prac­tice. Among other things, the is­sue of as­sign­ing the sta­tus of the “Ref­er­ence Cen­ter” for the HLA geno­typ­ing to the Cen­ter for Molec­u­lar Medicine and Cell Tech­nol­ogy is also un­der con­sid­er­a­tion given the level of equipment with the nec­es­sary equipment, the ma­te­rial and tech­ni­cal base and the pre­pared­ness of the staff.

It is note­wor­thy that by now the Cen­ter has be­come the largest re­search and de­vel­op­ment unit that car­ried out works to in­tro­duce and de­velop new high-tech di­ag­nos­tic and treat­ment meth­ods that rise hope to re­cover more pa­tients. To date, more than 25 joint re­search projects have been car­ried out here on the ba­sis of bi­lat­eral agree­ments with many lead­ing repub­li­can med­i­cal in­sti­tu­tions, such as Tashkent Med­i­cal Academy (Depart­ment of Neu­rol­ogy, Ob­stet­rics and Gyne­col­ogy, De­part­men­tal and Hos­pi­tal Ther­apy), Tashkent Pe­di­atric Med­i­cal In­sti­tute, Tashkent In­sti­tute of Ad­vanced Med­i­cal Ed­u­ca­tion, Tashkent Den­tal In­sti­tute, Repub­li­can Pe­di­atric In­sti­tute, Min­istry of Health of Uzbek­istan, med­i­cal in­sti­tutes of Sa­markand, Bukhara, Andi­jan, Khorezm, Repub­li­can Spe­cial­ized Sci­en­tific-prac­ti­cal Med­i­cal Cen­ter of Der­ma­tol­ogy and Venere­ol­ogy, Repub­li­can Screen­ing Cen­ter, Re­search Cen­ter for Emer­gency Med­i­cal Care, Repub­li­can Spe­cial­ized Re­search Cen­ter of Al­ler­gol­ogy, Repub­li­can Spe­cial­ized Sci­en­tific-Prac­ti­cal Med­i­cal Cen­ter of Ob­stet­rics and Gyne­col­ogy, Repub­li­can Spe­cial­ized Eye Mi­cro­surgery Cen­ter, Repub­li­can peri­na­tal cen­ter of the Min­istry of Health of the Repub­lic of Uzbek­istan.

Newspapers in English

Newspapers from Uzbekistan

© PressReader. All rights reserved.